-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Camostat Mesylate
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/59721-29-8.gif)
| Category | Influenza Virus |
| CAS | 59721-29-8 |
| Description | Camostat (INN) or FOY-305 is a serine protease inhibitor. Serine protease enzymes have a variety of functions in the body, and so camostat has a diverse range of uses. It is used in the treatment of some forms of cancer and is also effective against some viral infections, as well as inhibiting fibrosis in liver or kidney disease orpancreatitis. |
Product Information
| Synonyms | 4-(2-(2-(dimethylamino)-2-oxoethoxy)-2-oxoethyl)phenyl 4-guanidinobenzoate methanesulfonate; Camostat Mesilate; Camostat Mesylate; FOY 305; FOY-305; FOY305 |
| IUPAC Name | [4-[2-[2-(dimethylamino)-2-oxoethoxy]-2-oxoethyl]phenyl] 4-(diaminomethylideneamino)benzoate;methanesulfonic acid |
| Molecular Weight | 494.52 |
| Molecular Formula | C20H22N4O5.CH4O3S |
| Canonical SMILES | O=C(OCC(N(C)C)=O)CC1=CC=C(OC(C2=CC=C(NC(N)=N)C=C2)=O)C=C1.CS(=O)(O)=O |
| InChI | 1S/C20H22N4O5.CH4O3S/c1-24(2)17(25)12-28-18(26)11-13-3-9-16(10-4-13)29-19(27)14-5-7-15(8-6-14)23-20(21)22;1-5(2,3)4/h3-10H,11-12H2,1-2H3,(H4,21,22,23);1H3,(H,2,3,4) |
| InChIKey | FSEKIHNIDBATFG-UHFFFAOYSA-N |
| Boiling Point | 634.6°C at 760 mmHg |
| Melting Point | 162-164°C |
| Purity | >98% |
| Solubility | In Vitro: DMSO : 125 mg/mL(252.77 mM;Need ultrasonic) H2O : ≥ 50 mg/mL(101.11 mM) In Vivo: 1.Add each solvent one by one:PBS Solubility: 12.5 mg/mL (25.28 mM); Clear solution; Need ultrasonic 2.Add each solvent one by one:10% DMSO >> 40%PEG300 >> 5%Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.21 mM); Clear solution 3.Add each solvent one by one:10% DMSO >> 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.08 mg/mL (4.21 mM); Clear solution 4.Add each solvent one by one:10% DMSO >> 90%corn oil Solubility: ≥ 2.08 mg/mL (4.21 mM); Clear solution |
| Appearance | Solid powder |
| Application | Trypsin Inhibitors |
| Storage | 4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months -20°C, 1 month (sealed storage, away from moisture) |
| Complexity | 695 |
| Exact Mass | 494.14713497 |
| In Vitro | Camostat mesylate (Camostat mesilate) inhibits both monocyte chemoattractant protein-1 (MCP-1) and TNF-α production from monocytes, and proliferation and MCP-1 production from PSCs. Camostat mesylate, a trypsin-like protease inhibitor, provides a potent (IC50=50 nM) and prolongs attenuation of ENaC function in human airway epithelial cell models that is reversible upon the addition of excess trypsin. |
| In Vivo | Camostat mesilate (30 mg/kg; p.o.; twice a day for 9 days) blocks the spread and pathogenesis of SARS-CoV in a pathogenic mouse model. Camostat mesilate is effective in protecting mice against death due to a lethal infection by SARS-CoV, with a survival rate of ~60% |
| PSA | 197.56000 |
| Target | Ser/Thr Protease; SARS-CoV |
